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recurrent, debilitating abdominal pain, usually occurring within
the ﬁrst hour after meals. Hence its been also referred to as
intestinal angina.3 This is due to insufﬁcient visceral blood ﬂow
during periods of heightened intestinal demands.4 Therapeutic
options include surgical reconstruction and percutaneous trans-
luminal angioplasty (PTA) with or without stent placement.5 PTA
has become an alternative to surgery in many high risk surgical
patients. The procedural and clinical success rate of PTA has been
reported to be greater than 80% and 75%, respectively.6–8 In PTA
without stenting, restenosis of the dilated artery and recurrence of
symptoms occur in 17–50% of patients within the ﬁrst year.6–8 This
reduces the efﬁcacy and durability of balloon angioplasty. Matsu-
moto et al. reported from his case series comparing PTA with and
without stenting, that PTAwith stentingwas associatedwith lower
incidence of complications and a higher technical and clinical
success rate.9 We report our patient who was initially diagnosed
as a case of acid peptic disease (APD) and later as postprandial
angina secondary to coronary ischemia. Our patient actually had
SMA stenosis and occlusion presenting as APD and postprandial
angina. Patient successfully underwent PTA with stenting with
dramatic improvement. His 2 yrs follow-up with upper GI endo-
scopy showed normal gastroduodenal mucosa.
Conclusion: SMA stenosis, a rare condition, presents as recurrent
abdominal pain with postprandial angina, should be carefully
considered because of its serious clinical consequences. PTA with
stenting has been considered as a safe and effective treatment
alternative to surgery.
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Introduction: Clopidrogel is the most common, cost effective med-
ication available for patients undergoing PCI. But variations in
CYP2C19 has been associated in decreasedmetabolism of this drug
leading to MACE. The other anti-platelet drugs considered in such
situations include Prasugrel and Ticagrelor, which are highly efﬁ-
cient when compared to Clopidrogel but are sometimes associated
with bleeding andTicagrelor is expensive. CYP2C19*2/*3 is themost
common, loss of function mutation in this gene, which reduces its
activity and hence lowmetabolism of Clopidrogel. Patients hetero-
zygous to anyone of these SNPs have to be put on alternative
treatment regime, which included Prasugrel and Ticagrelor or
higher doses of Clopidrogel.
Objective: To evaluate the efﬁciency of Clopidrogel (75 mg), Prasu-
grel (10 mg) and Ticagrelor (90 mg) in PCI patients heterozygous for
CYP2C19*2/*3.
Methodology: A total of 20 patients who have undergone PCI and
heterozygous for CYP2C19*2 and CYP2C19*3 variations were
recruited fromSri Balaji Hospital, Chrompet after obtainingwritten
informed consent. The patients were randomly categorized into 3
regimens: double dose Clopidrogel (75 mg), Prasugrel (10 mg), and
Ticagrelor (90 mg). Each group has 8, 8, and 4 patients, respectively.
The efﬁcacy of these drugs was evaluated by platelet response
array using FACS. Based on platelet reactivity index (PRI), theywere
classiﬁed as normal (<50), borderline, or poor (>50) response.
Results: Of the 8 patients who had Clopidrogel (75 mg), two had
borderline response and the rest 6 had poor response, and of
the 8 patients, who were on Prasugrel (10 mg), two had borderline
and 6 had good response. The 4 patients on Ticagrelor had good
response.
Conclusion: Evaluation of the efﬁcacy of these three anti-platelet
drugs in the heterozygous group of CYP2C19*2/*3 showed Ticagre-
lor is highly efﬁcient in preventing platelet aggregation followed by
Prasugrel in our cohort. Patients on double dose Clopidogrel have
high residual platelet reactivity.
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Back ground: Clopidogrel is an prodrug that requires hepatic
bioactivation by several enzymes including CYP2C19. Clopidogrel,
which is currently the mainstay of management after PCI, fails in
certain group of individuals, as they are unable to metabolize the
drug. Variations in the gene CYP2C19 has been associated with
poor metabolism of clopidogrel and hence mace
Methods: A total of 151 patients who have undergone PCI were
recruited from our institution after obtaining written informed
consent. Salivary samples from patients were genotyped for
CYP2C19*2, CYP2C19*3 variations by sequencing method (GAAP
X METHOD). Dual antiplatelets were given based on genotype
information.
Results: Based on their genotyping result for CYP2C19*2 and
CYP2C19*3, patients were categorized into 3 groups – normal
(GG,GG), intermediate (AG), and poor (homozygous variant AA).
Percentage of individuals in each group was 29, 52, and 19, respec-
tively. Poor metabolizers were given newer agents (Prasugrel or
Ticagrelor). Intermediate metabolizers were given newer agents or
double dose clopidogrel. Out of 151 patients followed-up for 6
months, only 3 patients (1.5%) were admitted with myocardial
infarction (troponin positive). They all underwent CAG – one
patient had stent thrombosis. He was not compliant with anti-
platelets. Other two had lesions in non-culprit vessels with patent
stents.
Conclusion: Major adverse coronary events after PCI were brought
down signiﬁcantly by genotyping individuals. Genotype may be
relevant for choosing appropriate dual antiplatelet therapy in
patients undergoing PCI.
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Absorb biodegradable biovascular scaffold (BVS) is a relatively new
device in themanagement of coronary artery disease. Initially, BVS
was studied in chronic stable lesions. There is emerging data on its
usage in acute coronary syndrome lesion. Themanufacturer advo-
cates 5 Ps during deployment of the scaffold (proper sizing, pre-
dilatation, pay attention to expansion limit, post dilation with
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noncompliant (NC) balloon, and prescribe DAPT).Wehypothesized
that in selected ST elevation myocardial infarction (STEMI) lesions
it would be possible to do away with predilation (one of the Ps) and
this would be associated with reduced slow ﬂow.
Our protocol in STEMI is to pre-treat these patients with aspirin
chewable (325 mg) half tablet, if the patient is on aspirin, full tablet,
if the patient is not on aspirin plus prasugrel 60 mg or clopidogrel
300 mg or ticagrelor 90 mg 2 tabs in the ER. IV access is obtained.
After heparin 5000 IV is administered, the patients are shifted to
the cath lab. Right radial access is obtained. 6F sheath is placed. In
anterior wall MI, we proceed with the XB guiding catheter directly
(as per Direct study protocol). The patients are given Inj. Bivalur-
idin bolus followed by infusion. Heparin plus GP IIB inhibitors are
used in patients who do not receive bivaluridin. 2 orthogonal views
of the infarct related artery are obtained. The lesion is crossed and
thrombosuction is done. For direct BVS deployment, patient has to
satisfy the following criteria: Age< 55 years, no ﬂuoroscopic cal-
cium, no history of prior angina. All patients received intracoronary
(I/C) nikorandil 2 mg and NTG (100 mcg) as per the hemodynamic
status.TheScaffold lengthwaschosenasnormal tonormalvascular
segment. The diameter of the BVS was upsized by 0.5 mm then the
visual estimation of the vessel size. The BVS was deployed very
gradually up to (maximum) 12 atms pressure. I/C NTG/Nikorandil
was repeated. The scaffolds were post-dilated with noncompliant
balloon, over-sizing upto 0.5 mm-more the scaffold size matching
the vessel size. After completion of the BVS deployment, the RCA
angiogramwasobtained in anteriorwallMI. In inferiorwall,MI prior
angiogram of left coronary artery was done, then RCA was hooked,
and the procedure was completed.
Between Jan 2013 to July 2015, 52 scaffolds were deployed in
various lesions of STEMI. 13 scaffolds were deployed without
pre-dilatations of STEMI lesion. The mean ages of the patients
were 36–85 years. 10 were male, diabetes (3 patients), smoking (3
patients), hyperlipidemia (7 patients), obesity (3 patients) were the
coronary risk factors. The total ischemia time was 180  75.8 min.
The door to balloon time was 35  14.5 min. Pre-procedure TIMI
ﬂow as follows TIMI 0–7 patients TIMI I-1, TIMI II-2, and TIMI III-3
patients. Post-procedure ﬂow was TIMI II-1, patient TIMI III-2
patients. LVEF was 35  12% during acute phase, which improved
to 42  12% at 3 months. All the patients are found to be in NHYA
class I at 10 months of follow-up.
From this pilot project, we conclude that in selected STEMI lesions
it is feasible to deploy BVS without lesion pre-dilatation. This is
associated with good in hospital and intermediate term clinical
outcome. A randomized controlled trial is warranted.
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Background: Non-speciﬁc aortoarteritis (NSAA)/Takayasu arteritis
(TA) is an inﬂammatory arteriopathy common in young Asian
females affecting the aorta and its branches leading to signiﬁcant
ischemic events. Progressive NSAAmay lead to obstructive lesions
of all arch vessels leading to disabling neurologic symptoms. There
is limited experience with endovascular revascularization in this
situation. We report results of stent-supported angioplasty to
stenosis of sole surviving arch vessel performed in our center.
Methods: Angioplasty and stent placement were performed in 8
consecutive patients with TA (age, 11–42 years; mean, 28.3  4.1 y)
with cerebrovascular symptoms caused by severe stenotic lesions
of supraaortic (i.e., carotid, vertebral, and brachiocephalic) arteries
from May 2010 to May 2013.
Result: No immediate procedure-related complication orneurologic
deﬁcitsoccurred.Thesymptoms improvedinall patients.Onfollow-
up (mean, 25 7 months; range, 3–49 months), 6 patients were
asymptomatic and twopatients had recurrence of neurologic symp-
toms. These patients had in-stent restenosis of the carotid artery.
Conclusion: Stent-supported angioplasty of a sole supraaortic
artery is safe and feasible and provides good symptomatic relief
in patients with advanced NSAA.
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Introduction: Percutaneous coronary intervention has become
common in the management strategy of patients with chronic
total occlusion. However, despite improving techniques for open-
ing chronic total occlusions, the beneﬁt of successful recanaliza-
tion of the artery remains unclear.
Objectives: The purpose of this study was to know the procedural
success rates, guidewire strategies, in-hospital and one year out-
come of patients undergoing percutaneous coronary intervention
in chronic total occlusion.
Methods: CTO-PCI were attempted in 101 consecutive patients. 79
cases with successful PCI and 22 cases with unsuccessful PCI were
enrolled in the study from January 2013 to February 2013. Chronic
total occlusion was deﬁned as thrombolysis in myocardial infarc-
tion ﬂow grade 0-1 and duration >3 months. Detailed baseline
clinical, angiographic, procedural, and outcome data were col-
lected and compared success versus failed procedures.
Results: Procedural success was seen in 78% patients (79 of 101).
Patients with unsuccessful PCI compared to successful PCI were
mainly male (81.01% vs. 72.3%; p < 0.02), had a higher incidence of
diabetes mellitus (31.1% vs. 20.9%; p < 0.04) and hypertension
(53.3% vs. 42.3%; p < 0.04). Most patients in successful group had
single vessel disease (63.4% vs. 46.7%; p < 0.001) and less three-
vessel disease (11.8% vs. 22.8%) compared to unsuccessful group.
In-hospital MACE was insigniﬁcantly higher in unsuccessful PCI
(33.1% vs. 0%). Unsuccessful PCI was signiﬁcantly associated with
higher rate of one year MACE (61% vs. 18.1%, p = 0.01), especially
revascularization (33.3% vs. 12.2%, p = 0.02).
Conclusions: Patients with successful recanalization of CTO with
PCI have better symptom relief, better clinical outcome, improved
left ventricular function and better long-term survival compared
with patients in whom the attempt to recanalize CTO has failed.
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In the general hypertensive population, renal artery stenosis (RAS)
is the most common secondary cause of hypertension and is
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